Marwa Safwat
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marwa Safwat has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed Ali
Beni-Suef University
2 shared publications - Walid Hamdy Kilany
Affiliation: Reference Laboratory for Veterinary Quality Control on Poultry Production (NLQP), Animal Health Research Institute, P.O. Box, 264, Giza, Egypt
2 shared publications - Abdel-Satar Arafa
Reference Laboratory for Veterinary Quality Control on Poultry Production, Animal Health Research Institute, Agriculture Research Center, Giza 12618, Egypt
1 shared publication - Abdou Nagy
Department of Virology, Faculty of Veterinary Medicine, Zagazig University, Zagazig 44511, Egypt
1 shared publication - Al Hussien M. Dahshan
Poultry Diseases Department, Faculty of Veterinary Medicine, Beni-Suef University, Beni-Suef 62511, Egypt
1 shared publication - Awad Ali Shehata
Structural Membrane Biochemistry, Bavarian NMR Center, Technical University of Munich (TUM), 85748 Garching, Germany
1 shared publication
Latest Publications
- Open Access
Multivalent Inactivated Vaccine Protects Chickens from Distinct Clades of Highly Pathogenic Avian Influenza Subtypes H5N1 and H5N8
Background/Objective: Highly pathogenic avian influenza (HPAI) H5 subtype remains a significant menace to both the poultry industry and human public health. Biosecurity and mass vaccination of susceptible commercial poultry flocks are crucial to reduce the devastating economic loss and hinder the evolution of the virus. Methods: In this study, we developed a multivalent avian influenza virus (AIV) vaccine, including strains representing the HPAI 2.2.1.1., 2.2.1.2., and 2.3.4.4b clades circulating in Egypt and the Middle East. Specific pathogen-free (SPF) two-week-old chickens were vaccinated with a single vaccine shot and observed for four weeks post-vaccination before being challenged. The challenge experiment involved using one strain of HPAI H5N1 subtype clade 2.2.1.2 and two strains of HPAI H5N8 subtype clade 2.3.4.4b derived from chickens and ducks. To assess the vaccine’s potency and efficacy, the pre-challenge humoral immune response and post-challenge survival and virus shedding were evaluated. Results: All the vaccinated birds exhibited 100% seroconversion 2 weeks post-vaccination (2 WPV). In addition, protective antibody titers against each diagnostic antigen, i.e., 7.8 ± 1.8 (H5N1, clade 2.2.1.2), 10.0 ± 0.0 (H5N1, clade 2.2.1.1), and 7.5 ± 0.9 (H5N8, clade 2.3.4.4b) were detected 3 WPV. The vaccination achieved complete protection (100%) against all challenge viruses with no disease symptoms. The vaccinated birds exhibited a statistically significant reduction in oropharyngeal virus shedding 2 days post-challenge (DPC). Conclusions: This study illustrated that a single application of a multivalent genetic-matching whole AIV vaccine under laboratory conditions elicits adequate protection against the HPAI challenge, representing 2.2.1.2 and 2.3.4.4b clades. The developed vaccine has the potential to be a vaccine of choice against a broad range of HPAI in commercial flocks raised under field conditions in endemic areas.
Open AccessMultivalent Inactivated Vaccine Protects Chickens from Distinct Clades of Highly Pathogenic Avian Influenza Subtypes H5N1 and H5N8
Background/Objective: Highly pathogenic avian influenza (HPAI) H5 subtype remains a significant menace to both the poultry industry and human public health. Biosecurity and mass vaccination of susceptible commercial poultry flocks are crucial to reduce the devastating economic loss and hinder the evolution of the virus. Methods: In this study, we developed a multivalent avian influenza virus (AIV) vaccine, including strains representing the HPAI 2.2.1.1., 2.2.1.2., and 2.3.4.4b clades circulating in Egypt and the Middle East. Specific pathogen-free (SPF) two-week-old chickens were vaccinated with a single vaccine shot and observed for four weeks post-vaccination before being challenged. The challenge experiment involved using one strain of HPAI H5N1 subtype clade 2.2.1.2 and two strains of HPAI H5N8 subtype clade 2.3.4.4b derived from chickens and ducks. To assess the vaccine’s potency and efficacy, the pre-challenge humoral immune response and post-challenge survival and virus shedding were evaluated. Results: All the vaccinated birds exhibited 100% seroconversion 2 weeks post-vaccination (2 WPV). In addition, protective antibody titers against each diagnostic antigen, i.e., 7.8 ± 1.8 (H5N1, clade 2.2.1.2), 10.0 ± 0.0 (H5N1, clade 2.2.1.1), and 7.5 ± 0.9 (H5N8, clade 2.3.4.4b) were detected 3 WPV. The vaccination achieved complete protection (100%) against all challenge viruses with no disease symptoms. The vaccinated birds exhibited a statistically significant reduction in oropharyngeal virus shedding 2 days post-challenge (DPC). Conclusions: This study illustrated that a single application of a multivalent genetic-matching whole AIV vaccine under laboratory conditions elicits adequate protection against the HPAI challenge, representing 2.2.1.2 and 2.3.4.4b clades. The developed vaccine has the potential to be a vaccine of choice against a broad range of HPAI in commercial flocks raised under field conditions in endemic areas.
- Open Access
- 1 October 2023
- Published by Egyptian Knowledge Bank in Egyptian Journal of Animal Health
- Vol. 3 (4) , 136-147
Highlight on Reticuloendotheliosis virus (REV) in commercial chicken flocks
In this study, the reticuloendotheliosis (REV) infection status was monitored through antibody determination and molecular detection in chickens in different provinces of Egypt. We investigated the occurrence and genetic characteristics of REVs in chickens’ flocks from January 2019 to March 2021 as a PCR test examined 39 commercial chicken farms (27 layers and 12 broiler breeders) from 11 provinces of Egypt. Results showed six farms (15.4%) were REV-positive in 3 provinces (AL Sharqia, Al Menya, and Al Behera). Four REV-positive farms were genetically sequenced.24 of these 39 farms (18 layers and 6 broiler breeders) were examined by ELISA test for antibodies detection against REV and ALV (subtype A and B). 22 farms (91.7%) were REV antibodies positive in all 11 provinces tested (Al Sharqiyah, Al Monofiya, Al Daqahlia, Al Gharbia, Al Qualiobia, Al Beheira, Giza, Damietta, Kafr El Sheikh, Bani Suief and El Minya), 3 farms (12.5%) were ALV (subtype A and B) antibodies positive from Al Beheira governorates. Molecular detection of REV was differentiated from other neoplastic viruses MD, ALV (subtype A, B, C, D, and J), from 39 farms, seven farms were positive for MDV (5 of them were seropositive for REV), one farm positive for ALV.J (the farm was seropositive for REV), all farms were negative for ALV.Our results demonstrated that REV was extensively distributed in different regions of Egypt. Phylogenetic analysis of the partially sequenced envelope glycoprotein gene showed that REV was most closely related to strains from China, Taiwan, Thailand, and the USA. The REV strains were clustered into REV subtype III. This finding indicates that REV subtype III was predominantly circulated in Egyptian chicken flocks. Our findings raise awareness about REV-induced diseases as the causative agent of runting and oncogenic disease in chickens and highlight the incidence of REV infection among some commercial chicken flocks in Egypt.
- 1 October 2023
- Published by Egyptian Knowledge Bank in Egyptian Journal of Animal Health
- Vol. 3 (4) , 136-147
Open AccessHighlight on Reticuloendotheliosis virus (REV) in commercial chicken flocks
In this study, the reticuloendotheliosis (REV) infection status was monitored through antibody determination and molecular detection in chickens in different provinces of Egypt. We investigated the occurrence and genetic characteristics of REVs in chickens’ flocks from January 2019 to March 2021 as a PCR test examined 39 commercial chicken farms (27 layers and 12 broiler breeders) from 11 provinces of Egypt. Results showed six farms (15.4%) were REV-positive in 3 provinces (AL Sharqia, Al Menya, and Al Behera). Four REV-positive farms were genetically sequenced.24 of these 39 farms (18 layers and 6 broiler breeders) were examined by ELISA test for antibodies detection against REV and ALV (subtype A and B). 22 farms (91.7%) were REV antibodies positive in all 11 provinces tested (Al Sharqiyah, Al Monofiya, Al Daqahlia, Al Gharbia, Al Qualiobia, Al Beheira, Giza, Damietta, Kafr El Sheikh, Bani Suief and El Minya), 3 farms (12.5%) were ALV (subtype A and B) antibodies positive from Al Beheira governorates. Molecular detection of REV was differentiated from other neoplastic viruses MD, ALV (subtype A, B, C, D, and J), from 39 farms, seven farms were positive for MDV (5 of them were seropositive for REV), one farm positive for ALV.J (the farm was seropositive for REV), all farms were negative for ALV.Our results demonstrated that REV was extensively distributed in different regions of Egypt. Phylogenetic analysis of the partially sequenced envelope glycoprotein gene showed that REV was most closely related to strains from China, Taiwan, Thailand, and the USA. The REV strains were clustered into REV subtype III. This finding indicates that REV subtype III was predominantly circulated in Egyptian chicken flocks. Our findings raise awareness about REV-induced diseases as the causative agent of runting and oncogenic disease in chickens and highlight the incidence of REV infection among some commercial chicken flocks in Egypt.
- Open Access
- 5 January 2019
- Published by Veterinary World in Veterinary World
- Vol. 12 (1) , 97-105
Combined H5ND inactivated vaccine protects chickens against challenge by different clades of highly pathogenic avian influenza viruses subtype H5 and virulent Newcastle disease virus
Aim: The aim of the current study was to evaluate the efficacy of a trivalent-inactivated oil-emulsion vaccine against challenge by different clades highly pathogenic avian influenza (HPAI) viruses including HPAI-H5N8 and the virulent genotype VII Newcastle disease virus (NDV) (vNDV). Materials and Methods: The vaccine studied herein is composed of reassortant AI viruses rgA/Chicken/Egypt/ ME1010/2016 (clade 2.2.1.1), H5N1 rgA/Chicken/Egypt/RG-173CAL/2017 (clade 2.2.1.2), and "NDV" (LaSota NDV/ CK/Egypt/11478AF/11); all used at a concentration of 108 EID50/bird and mixed with Montanide-ISA70 oil adjuvant. Two-week-old specific pathogen free (SPF) chickens were immunized subcutaneously with 0.5 ml of the vaccine, and hemagglutination inhibition (HI) antibody titers were monitored weekly. The intranasal challenge was conducted 4 weeks post-vaccination (PV) using 106 EID50/0.1 ml of the different virulent HPAI-H5N1 viruses representing clades 2.2.1, 2.2.1.1, 2.2.1.2, 2.3.4.4b-H5N8, and the vNDV. Results: The vaccine induced HI antibody titers of >6log2 against both H5N1 and NDV viruses at 2 weeks PV. Clinical protection against all HPAI H5N1 viruses and vNDV was 100%, except for HPAI H5N1 clade-2.2.1 and HPAI H5N8 clade- 2.3.4.4b viruses that showed 93.3% protection. Challenged SPF chickens showed significant decreases in the virus shedding titers up to <3log10 compared to challenge control chickens. No virus shedding was detected 6 "days post-challenge" in all vaccinated challenged groups. Conclusion: Our results indicate that the trivalent H5ND vaccine provides significant clinical protection against different clades of the HPAI viruses including the newly emerging H5N8 HPAI virus. Availability of such potent multivalent oil-emulsion vaccine offers an effective tool against HPAI control in endemic countries and promises simpler vaccination programs.
- 5 January 2019
- Published by Veterinary World in Veterinary World
- Vol. 12 (1) , 97-105
Open AccessCombined H5ND inactivated vaccine protects chickens against challenge by different clades of highly pathogenic avian influenza viruses subtype H5 and virulent Newcastle disease virus
Aim: The aim of the current study was to evaluate the efficacy of a trivalent-inactivated oil-emulsion vaccine against challenge by different clades highly pathogenic avian influenza (HPAI) viruses including HPAI-H5N8 and the virulent genotype VII Newcastle disease virus (NDV) (vNDV). Materials and Methods: The vaccine studied herein is composed of reassortant AI viruses rgA/Chicken/Egypt/ ME1010/2016 (clade 2.2.1.1), H5N1 rgA/Chicken/Egypt/RG-173CAL/2017 (clade 2.2.1.2), and "NDV" (LaSota NDV/ CK/Egypt/11478AF/11); all used at a concentration of 108 EID50/bird and mixed with Montanide-ISA70 oil adjuvant. Two-week-old specific pathogen free (SPF) chickens were immunized subcutaneously with 0.5 ml of the vaccine, and hemagglutination inhibition (HI) antibody titers were monitored weekly. The intranasal challenge was conducted 4 weeks post-vaccination (PV) using 106 EID50/0.1 ml of the different virulent HPAI-H5N1 viruses representing clades 2.2.1, 2.2.1.1, 2.2.1.2, 2.3.4.4b-H5N8, and the vNDV. Results: The vaccine induced HI antibody titers of >6log2 against both H5N1 and NDV viruses at 2 weeks PV. Clinical protection against all HPAI H5N1 viruses and vNDV was 100%, except for HPAI H5N1 clade-2.2.1 and HPAI H5N8 clade- 2.3.4.4b viruses that showed 93.3% protection. Challenged SPF chickens showed significant decreases in the virus shedding titers up to <3log10 compared to challenge control chickens. No virus shedding was detected 6 "days post-challenge" in all vaccinated challenged groups. Conclusion: Our results indicate that the trivalent H5ND vaccine provides significant clinical protection against different clades of the HPAI viruses including the newly emerging H5N8 HPAI virus. Availability of such potent multivalent oil-emulsion vaccine offers an effective tool against HPAI control in endemic countries and promises simpler vaccination programs.